Healthy Skepticism Library item: 10149

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Coombes R.
Cancer drugs: swallowing big pharma's line?
BMJ 2007 May 19; 334:(7602):1034
http://www.bmj.com/cgi/content/full/334/7602/1034

Abstract:

The media lapped up a report last week criticising the UK’s record on cancer treatment. Rebecca Coombes unpicks the latest round of NICE bashing

When a report last week put the United Kingdom near the bottom of a league of developed nations for giving patients access to new cancer drugs, the press were more than happy to spread the bad news.

The drug company funded report from the Karolinska Institute, Stockholm, received a largely uncritical reception by UK newspapers, broadsheet and tabloids alike. “Cancer survival rates are worst in western Europe,” splashed the Daily Telegraph on its front page. The UK was the “sick man of Europe” for providing cancer drugs, said the Independent.

The report, paid for by Roche and published in the Annals of Oncology (volume 18, supplement 3, 2007), covers 25 countries, including Australia, Canada, New Zealand, South Africa, and the United States, as well as 19 European countries, and looks at access to 67 “innovative” cancer drugs. In its final verdict, the UK was yoked with Poland and the . . .